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PSY56
A SYStemAtic Review on the effect of BehAvioRAl veRSuS SuRgicAl 
inteRvention on oBeSe PAtientS’ PSYchologicAl well-Being
Fortier K.J., Kiss N.
Oxford Outcomes, Morristown, NJ, USA
Objectives: Approximately 400 million people worldwide are considered obese as 
defined by the World Health Organization. In Europe, 15.5% of adults have a body 
mass index of ≥ 30 kg/m2. Diabetes, heart disease, and stroke, are among the most 
common obesity-related comorbidities. Furthermore, obesity has also been found 
to cause depression and emotional distress, negatively affecting the quality of life 
of obese patients. With obesity at the forefront of many social and health care dia-
logues, treatment guidelines currently suggest exercise (often linked with changes 
in diet) or weight loss surgery to effectively treat obesity. This review seeks to under-
stand which of these two types of interventions, exercise or surgical, have a greater 
impact on obese patients’ emotional and psychological well-being. MethOds: A 
systematic review of peer-reviewed literature was conducted to identify RCTs and 
observational studies that measure any type of emotional or psychological change 
in patients who underwent either of the interventions of interest for weight loss: 
exercise or weight loss surgery. Embase and Medline databases were searched for 
articles published from 2004 to 2013. Search terms were used to identify studies 
that assessed psychological well-being of obese patients who either exercised or 
underwent weight loss surgery. Results: The search identified 40 studies, of which 
11 measured relevant interventions and measures of psychological well-being. Of 
those, 9 investigated patients undergoing bariatric surgery, while only 2 explored 
exercise interventions. All of the studies indicated improvements in patients’ emo-
tional health, except for 1 bariatric surgery study, where patients were shown to 
have no change in symptoms after weight loss plateaued. cOnclusiOns: While 
both interventions, when they lead to weight loss, seem to result in improvements 
in patients’ psychological well-being, there is limited data to conclude whether one 
intervention is more effective in improving psychological well-being. Further study 
is needed, especially for exercise interventions.
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Objectives: According to the Centers for Disease Control and Prevention, there 
were dramatic increases in the obesity rates in the US since 1980s which reached 
a plateau after 20031. The objectives of this study were to examine obesity trends 
across US adults from 2006-2012 by various gender/age groups and changes in 
activity impairment. MethOds: Results were from the US National Health and 
Wellness Survey, a nationally representative, online survey. Respondents were age 
≥ 18 years, and results were weighted/projected to reflect the gender, age, and race/
ethnic proportions, as determined by the Current Population Survey (US Census 
Bureau). This analysis focused on adults age ≥ 20 by BMI Class 1 (BMI> = 30 & < 35 
kg/m2), Class 2 (BMI> = 35 & < 40 kg/m2), and Class 3 (BMI> = 40 kg/m2). Activity 
impairment was assessed from the Work Productivity and Activity Impairment 
Questionnaire. Results: The proportions of adults age 20+ with Class 1, Class 2 
and Class 3 obesity levels have slowly declined from 2006 to 2012 (Class 1: 19.3% in 
2006 to 18.4% in 2012; Class 2: 9.2% in 2006 to 8.2% in 2012; Class 3: 7.3% in 2006 to 
6.7% in 2012). This is consistent across most age/gender subgroups, except in the 
group of men age 60+, which showed increases of Class 2 (7.5% to 8.2%) and Class 
3 obesity (3.7% to 4.6%); Activity impairment declined along with the decline of 
obesity prevalence (men and women), though women reported greater impairment 
than men in the corresponding BMI Class. cOnclusiOns: The data suggested a 
slight decline in obesity prevalence and improvement in activity function in the US 
population recently. However, obesity remains a pandemic with tremendous health 
and economic burden and calls for continuous effort in education, prevention and 
management. References 1 Centers for Disease Control and Prevention. Referenced 
June 11, 2013. http://www.cdc.gov/obesity/data/facts.html
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Objectives: To evaluate to what extent pain severity was associated with impair-
ment of regular daily activities other than paid work. MethOds: Study data 
originated from a prospective, non-interventional study of people with NP treated 
with the capsaicin patch QUTENZATM. Repeated observations from baseline- and 
12-week follow-up assessments for the Numerical Pain Rating Scale (NPRS) ‘aver-
age pain in the last 24 hours’ score, and the Activity Impairment (AI) score from 
the Work Productivity Activity Index (WPAI-NP) were analysed. The NPRS sub-
jectively records pain on a scale between 0 (no pain ) and 10 (worst imaginable 
pain). The WPAI-NP Activity Impairment Index measured the extent to which NP 
affected regular daily activities from 0% (no effect) to 100% (complete prevention). 
Generalized linear mixed models (GLMM; SPSS v20), with a normal probability 
distribution, identity link function, and a first-order autoregressive covariance 
structure were tested to determine the relationship between WPAI-NP-AI (scale) 
and NPRS (ordinal). Results: A total of 171 patients with NP contributed 253 com-
bined observations from baseline and week 12 follow-up assessment. Mean age 
at baseline was 59.4 years (sd 14.9) and 44% of subjects were male. The GLMM 
model that best fitted the data (smallest information criterion) had one random 
effect (subject+intercept) and two fixed effects (Sex+NPRS+intercept). The signifi-
cant (p< 0.05) fixed-effects coefficients were: (Intercept) 14.2+(Male: β -7.0; 95%CI 
-13.5,-0.5)+(NPRS3: 24.4;9.0,39.8)+(NPRS4:9.4;13.5,45.3)+(NPRS5:36.5;21.2,51.8)+(NP
Objectives: To identify and evaluate the published evidence base on the use of 
preference based measures for assessing haemophilia related outcomes, and to 
discuss their limitations and gaps for evidence based decision making. MethOds: A 
systematic review was carried out for 25 year time period 1988 to 2013 to investigate 
preference based evaluations of treatments and/or outcomes related to haemo-
philia. The search terms included:utility, QALY, standard gamble, time-trade-off, 
contingent valuation, conjoint analysis, and discrete choice. Results: The search 
identified 22 original peer reviewed articles, covering a range of countries and treat-
ments. There were 7 cost-utility analyses, and 7 studies reporting use of the EQ 5D 
to determine utility values for haemophilia health states. Two studies, both from 
Canada, were vignette type studies that directly assessed utilities for treatment 
related health states. The EQ 5D studies produced reasonably consistent utilities, 
whereas the vignette studies produced variable results. Six studies were conjoint 
analysis and/or willingness to pay studies and focused on the value of attributes of 
new treatments. As is typical of studies in rare diseases, there were limitations in 
all studies related mainly to small sample sizes, uncontrolled designs and poten-
tially confounding factors. The main evidence gaps were a lack of preference/util-
ity data for caregivers, or the direct impact of bleeding on utilities, and only one 
study used a generic measure other than the EQ 5D (the SF-6D) to generate utilities 
for haemophilia health states. cOnclusiOns: Given that haemophilia is a rare 
condition, there is a reasonably large evidence base of preference based studies 
for potential use in evidence based decision making. However, the limitations and 
gaps in the studies identified mean that there are still limitations in the evidence 
base to support a comprehensive assessment of the value of new interventions 
for haemophilia.
PSY54
PAtientS At the centeR of RegulAtoRY deciSionS: uSing StAted-
PRefeRence dAtA to helP RegulAtoRS AnSweR difficult QueStionS
González J.M.1, Johnson F.R.1, Fairchild A.1, Irony T.2, Ho M.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2US Food and Drug Administration, Silver 
Spring, MD, USA
Objectives: In collaboration with FDA’s Center for Devices and Radiological 
Health (CDRH), we developed and administered a best-practice discrete-choice 
experiment (DCE) survey to elicit preferences for outcomes associated with using 
weight-loss devices to demonstrate how DCE data can help determine meaningful 
benefits for regulatory decisions involving serious side-effect risks. MethOds: An 
online DCE questionnaire was administered to adult residents of the United States 
who reported having or having had a body mass index (BMI) of at least 30 kg/m2. 
Respondents evaluated constructed hypothetical weight-loss devices with different 
features identified with the help of clinicians at CDRH. Weight-loss devices were 
defined in terms of device effectiveness, device-related risks of side effects, sur-
gery requirements for implantation, and diet restrictions. An efficient experimental 
design ensured that device profiles provided the necessary statistical information to 
identify the choice-model parameters. Random-parameter choice models produced 
preference weights indicating the strength of preference for device features. These 
weights were used to calculate the maximum acceptable risk of dying or minimum 
required weight loss associated with various device profiles. Results: A total of 
540 respondents completed the online survey. Results from the study show that 
respondents had well-defined, plausible preferences for different outcomes associ-
ated with weight-loss devices. Internal validity tests, including a scope test of sensi-
tivity to absolute risk levels, indicated the data are of high quality. Preference results 
were used to construct an Excel-based tool that calculates the necessary benefits to 
offset the device-related risks with confidence intervals for any device that can be 
described by features included in the study design. cOnclusiOns: Results confirm 
the feasibility of using DCE methods to evaluate patients’ tolerance for weight-loss 
device risks, as well as the feasibility of constructing a policy-relevant decision aid 
that makes this information accessible to regulators.
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Objectives: Bosutinib a dual Src/Abl tyrosine kinase inhibitor (TKI) demonstrated 
efficacy in a phase 1/2 study of patients with relapsed/refractory Chronic Myeloid 
Leukemia (CML). Health utilities were reported in the imatinib IRIS study, but there 
is limited information from relapsed/refractory CML patients. The objective was to 
evaluate the effect of bosutinib on health utilities in patients with CML after failure 
with imatinib. MethOds: Evaluation of patient HRQoL was an exploratory objective 
in the clinical trial measured using the EQ-5D, which consists of 5-items: mobil-
ity, self-care, usual activities, pain/discomfort and anxiety/depression. Each item 
ranges from 1 (“no problems”) to 3 (“extreme problems”). The EQ-5D was completed 
at weeks 4, 8, 12 and every 12 weeks thereafter, as well as treatment completion 
and scored according to the UK tariff. Results: Of the N= 570 patients included 
in the trial, 288 were second line chronic phase (CP 2L) CML, 118 were third line 
CP patients (3L), 76 were accelerated phase (AP) and 64 blast phase (BP). For 2L 
patients, the mean utility score at baseline was 0.83 (SD 0.21), and was maintained 
throughout the course of the study demonstrating a significant improvement at 
week 36 (mean change from baseline 0.04, p= 0.01). For 3L patients, the mean utility 
at baseline was 0.80 (SD 0.22), and maintained throughout the study. There were no 
statistically significant differences from baseline through week 36 in health util-
ity in 3L patients. The mean utility at baseline for advanced patients was 0.78 (SD 
0.28) for AP and 0.66 (SD 0.30) for BP patients and was maintained throughout the 
study. cOnclusiOns: These data suggest that relapsed/refractory CML patients 
treated with bosutinib maintain their quality of life throughout the trial regardless 
of the line of treatment or phase of disease. These results highlight the value of 
capturing patient HRQoL in CML treatment.
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were used to compare outcomes across satisfaction groups. Results: Only 64 (4.08%) 
were satisfied with their treatment, and 1504 (95.92%) not satisfied. A positive relation-
ship was observed between satisfaction and HRQoL, with the most satisfied group 
recording a 31.62% higher EQ-5D score (mean 0.75 vs. 0.57, p< 0.01) relative to the next 
most-satisfied group. A negative relationship was observed between satisfaction and 
pain, with the most satisfied patient group scoring 30.89% lower pain scores (mean 
3.40 vs. 4.91, p< 0.01). cOnclusiOns: Most neuropathic pain patients are not satis-
fied with their current pain therapy. This analysis suggests a negative relationship 
between treatment satisfaction and reported pain severity as well as a clear positive 
relationship between treatment satisfaction and health related quality of life. The 
results highlight the need for a more targeted treatment of neuropathic pain patients.
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Objectives: According to the Pain in Europe Study, about one in five EU adults 
have chronic pain. Back pain / lower back pain is among the most commonly cited 
location of pain.1 Additionally, research has suggested that pain has a negative 
impact on sufferer mental health, employment, sleep and personal relationships.2 
This analysis profiles and compares adults experiencing back pain to adults with-
out pain across 5EU. MethOds: Results were taken from the 2011 5EU National 
Health and Wellness Survey, a nationally representative, self-administered survey. 
Respondents were adults age 18 and over from France, Germany, Italy, Spain and 
UK. This analysis focuses on adults diagnosed with back pain or experienced pain 
as a result of back problem in the past month- (“patients with back pain”). Quality 
of life was measured using the SF12v2 scale. Activity impairment was measured 
using the Work Productivity and Activity Impairment scale. Results: Out of the 
total sample of n= 57,512, ~10% (n= 5,984) have back pain. Relative to adults without 
pain, back pain sufferers are older on average (48.9 vs. 46.3), more likely to be women 
(57% vs. 48%), and obese (27% vs. 16%). Their overall mental and physical quality of 
life scores are significantly lower (43.2 vs. 47.9, p < 0.001 and 40.3 vs. 50.9, p < 0.001). 
In addition, back pain sufferers are exhibited more work impairment (absenteeism 
and presenteeism) and activity impairment, and utilized health care resources to a 
greater extent than non-sufferers (i.e., greater physician visits, hospitalization, and 
ER). All these results are notably higher among back pain patients treated with a pre-
scription. cOnclusiOns: Considering the prevalence of back pain among adults, 
the level of work impairment and quality of life limitations impacts a substantial 
portion of adults in the 5EU population. Improvements in treatment of back pain 
are needed to reduce this burden.
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Objectives: Reversal of the residual effect of rocuronium or vecuronium by neostig-
mine may be slow and associated with side-effects. Sugammadex, a selective relaxant 
binding agent, encapsulates rocuronium to provide for a rapid reversal of residual 
neuromuscular blockade. Also, postoperative residual neuromuscular block can 
reduce delay of awakening, recovery, and dissatisfaction of patient. The aim of this 
study is to evaluate the willingness-to-pay (WTP) of sugammadex for effectiveness 
and safety using a contingent valuation method. MethOds: A total of 505 adult 
general population and 60 experts (anesthesiologist and surgeon) participated in 
a face-to-face survey. The respondents were surveyed separately each scenario of 
moderate and deep blocks for surgery. The scenario was designed to provide informa-
tion concerning reversal time on neuromuscular block, adverse reaction of PRNB, and 
quality of surgery or recovery. The out-of-pocket WTP for sugammadex was utilized 
open answer. Results: In general population, WTP values for sugammadex were 
81,768 Korean won (KRW) in moderate block and 128,622 KRW in deep block. The same 
sample answered 89,017 KRW and 141,536 KRW for WTP for their family members 
in moderate block and deep block, respectively. Experts were estimated the WTP of 
99,417 KRW in moderate block and 153,250 KRW in deep block. For patients, experts 
suggested that 82,517 KRW and 132,517 KRW were appropriate WTP. The WTP was sta-
tistically significantly higher in the general population who had been taken operation 
and older than their counterparts. cOnclusiOns: The WTP for sugammadex was 
ranged the 81,768 to 99,417 KRW in moderate block, and the 128,622 to 153,250 KRW 
in deep block. The WTP of general population for their family members was higher 
than the WTP for their own, and the expert’s WTP was higher than their patients.
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Objectives: To assess rheumatologist perception towards biosimilars and the 
likelihood of use of biosimilars to manage RA patients in the EU, Brazil, Japan and 
China. MethOds: A multi-country cross-sectional survey was conducted in top-5 
EU countries (UK/Germany/Spain/France/Italy), Brazil, Japan and China in April/
May 2013 using an online physician panel in the respective geographies; rheu-
matologists were randomly selected for survey participation to be geographically 
representative in select countries/regions. Surveys assessed the rheumatologist 
perceptions of biosimilars in terms of factors that would prevent them from using 
RS6:43.7;28.5,60.0)+(NPRS7: 46.3;31.1,61.5)+(NPRS8: 58.5;42.6,74.4)+(NPRS9:2.0;44.2,
79.8)+(NPRS10:72.2;54.7,89.7). The estimated marginal mean WPAI-NP-AI increased 
linearly from 10.1% at NPRS 0 to 84.8% at NPRS 10. Predicted WPAI-NP-AI was highly 
correlated with observed values (R-squared= 0.889); mean absolute error (predicted-
observed) was 9.6 (sd 6.9). cOnclusiOns: In people with chronic NP, increasing 
pain severity was associated with a linear increase in impairment of regular daily 
activities other than paid work. Interventions that reduce pain are likely to improve 
functioning.
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Objectives: Bariatric surgery is the best long-term treatment for morbid obesity 
with clinical improves, like reductions in blood pressure, glucose and lipids levels. 
However postoperative complications and psychosocial issues may impact qual-
ity of life (QoL). This study aims to assess health-related quality of life (HRQoL) in 
Brazilian obese patients submitted to bariatric surgery. MethOds: A systematic 
review was conducted by April 2013 through Cochrane Collaboration, Medline, 
EMBASE, and Lilacs databases. Studies that described QoL in Brazilian obese 
patients were included in this review. Bariatric Analysis and Reporting Outcome 
System (BAROS), Moorehead-Ardelt quality of life questionnaire II (M-A-QoLQII), 
Abbreviated WHOQoL questionnaire and Short Form-6D (SF-6D) were used to evalu-
ate the behavior of patients who underwent bariatric surgery in relation to QoL 
domains. Results: Seven studies met eligibility criteria. In all studies, individuals 
presented body mass index (BMI) ≥ 40kg/m2 or ≥ 35 kg/m2 associated with comor-
bidities. Patients reported their self-esteem (SE), physical activity (PA), social rela-
tions (SR), disposition to work (DW) and sexual activity (SA), after bariatric surgery. 
According to the M-A-QoLQII, three studies showed HRQoL improvement in 28.9%, 
39.5%, 28.4%, 30% and 25.6% of patients for SE, PA, SR, DW and SA, respectively. 
And 68.9%, 50.6%, 53.1%, 52.2%, 45.6% of patients guaranteed greatly improved 
regarding those parameters, respectively. After weight loss, bariatric surgery was 
effective to improve QoL in PA domain. Besides, when compared to patients submit-
ted to medical treatment, patients who underwent surgical procedure presented 
an improvement of 93% in HRQoL, contrasting with 65.4% of the medical cohort 
(p< 0.001). Only one study measured QoL before and after bariatric surgery: SF-36 
domains and M-A-QoLQII showed that post-surgery results were invariably better 
than pre-surgery ones (p< 0.001 for all domains). cOnclusiOns: The present review 
demonstrated the potential QoL improvements in Brazilian patients after bariatric 
surgery, in addition to clinical benefits.
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Objectives: To analyze the cost of therapy for patients with chronic myeloid 
leukemia (CML) and their quality of life. MethOds: It is retrospective as regard 
to cost and prospective as regard to quality of life analysis. Five university hospi-
tals in four major cities treating all 320 CML-patients are included for the period 
2011-2012. Information is collected from the patients’ records about the health 
care resources used as medicines for CML, additional therapy, hospitalizations 
and physicians visits. The assessment of health related quality of life is con-
ducted with validated for the country SF-36 questionnaire. Results: A total of 
164 (51.2%) men and 156 (48.75%) women, average age 53.96±15.41 were observed. 
The average CML pharmacotherapy monthly cost is 5976.4 BGN, the average total 
pharmacotherapy cost for additional diseases is 566.27 BGN and the average addi-
tional costs for physicians’ visits and hospitalization is equal to 1504.69 BGN. The 
most expensive CML therapy is with Dasatinib 7771.20 BGN and the cheapest is 
Imatinib therapy equal to 5245.15 BGN. The most common additional diseases are 
cardiovascular (68%), followed by endocrine (29%). There is significant correlation 
between overall assessment for quality of life and average total additional costs 
– the higher assessment for QoL, the lower costs for hospitalization and visits. 
With the significantly highest score is the scale Bodily pain, followed by Physical 
functioning, and the lowest are Vitality, energy or fatigue and Role limitation. In 
most of patients on Imatinib (77.9%) are recorded good hematological responses 
and 66.7% are with major molecular response. cOnclusiOns: CML is a disease 
consuming significant health care resources especially for major pharmacother-
apy with TKIs. Infrequent physicians’ visits and rarer hospitalizations generate 
higher assessment of quality of life.
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tReAtment SAtiSfAction And itS ASSociAtion with heAlth outcomeS 
in PAtientS with neuRoPAthic PAin
Holbrook T.1, Obradovic M.2, Liedgens H.2
1ADELPHI REAL WORLD, MACCLESFIELD, UK, 2Grünenthal GmbH, Aachen, Germany
Objectives: Neuropathic pain (NP) is a chronic progressive disease which is hard 
to control. This analysis investigates patients’ satisfaction with pain therapy and its 
relationship with pain severity and health related quality of life (HRQoL). MethOds: 
Data were drawn from the 2012 Adelphi NP Disease Specific Programme, a cross-
sectional study involving 413 primary care physicians and specialists across Europe. 
Physicians provided detailed records for 3956 NP patients, of which 1568 patients 
voluntarily completed EQ-5D and Brief Pain Inventory questionnaires. HRQoL was 
measured via the EQ-5D, satisfaction via a three-option question answered by the 
patient, and pain via the Brief Pain Inventory (BPI) interference score. Boxplot analyses 
